Contraception News and Research

Latest Contraception News and Research

Podcast: KHN’s ‘What the Health?’ Health policy goes to court

A federal judge in Texas seemed sympathetic to the argument by GOP state officials that the Affordable Care Act soon will no longer be constitutional since Congress eliminated the penalty for not having insurance. The case was filed by 18 state attorneys general and two governors.

6 Sep 2018

Medicaid expansion may fill gap in reproductive health care access, study finds

Medicaid expansion may fill a significant gap in reproductive health care access, especially among young and low-income women, a new Michigan Medicine study finds.

31 Aug 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

Pregnant women with heart disease must give birth at 40 weeks gestation

Pregnant women with heart disease should give birth at no later than 40 weeks gestation. That is one of the recommendations in the 2018 European Society of Cardiology Guidelines for the management of cardiovascular diseases during pregnancy published online today in European Heart Journal, and on the ESC website.

25 Aug 2018

Biorhythms and birth control: FDA stirs debate by approving ‘natural’ app

The Food and Drug Administration took a "big tent" approach earlier this month when it approved two new forms of birth control that prevent pregnancy in very different ways.

21 Aug 2018

Digital birth control app gets FDA nod

Last week the United States Food and Drug Administration (FDA) announced its approval of the digital birth control app to be sold in the US. The app is called “Natural Cycles” and is one of the first medical devices of this kind to receive the FDA nod.

14 Aug 2018

Study finds increased rate of repeat pregnancies in women with intellectual and developmental disabilities

Women with intellectual and developmental disabilities have nearly double the rate of having another baby within a year of delivering compared to women without such disabilities, according to a new study published in CMAJ.

13 Aug 2018

FDA permits marketing of first mobile medical app for contraceptive use to prevent pregnancy

The U.S. Food and Drug Administration today permitted marketing of the first mobile medical application (app) that can be used as a method of contraception to prevent pregnancy.

13 Aug 2018

FDA approves first vaginal ring contraceptive that can be used for one year

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

10 Aug 2018

FDA approves first therapy for patients with rare tumors of the adrenal gland

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy.

31 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Combe announces launch of Preventeza Emergency Contraceptive and campaign

Combe Inc., the makers of Vagisil, today announced the launch of its Preventeza Emergency Contraceptive #WeAre1in2 campaign to showcase solidarity around women's reproductive rights.

6 Jul 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

The ‘perfect storm’: Redirecting family planning funds could undercut STD fight

A Trump administration effort to shift family planning funding toward groups that may not provide comprehensive services and away from organizations that provide abortions could cripple other federal efforts to curb an explosion in sexually transmitted diseases, some public health officials fear.

12 Jun 2018

‘Where the need is’: Tackling teen pregnancy with a midwife at school

The student comes in for a pregnancy test — the second time she has asked for one in a matter of weeks. She’s 15. She lives with her boyfriend. He wants kids — he won’t use protection. She loves him, she says. But she doesn’t want to get pregnant. She knows how much harder it would be for her to finish high school.

12 Jun 2018

Syphilis and gonorrhea on the rise in England

Both sexually transmitted infections (STIs), syphilis and gonorrhoea, are on the rise in modern England, staging a comeback from the Victorian era. Over the past one year, there has been a 20 percent rise in the incidence of STIs. The rates of syphilis for example is on a 70 year high last year according to the Public Health England statistics.

6 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018